Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

Abstract

A multicenter, randomized, investigator-masked, parallel-group trial compared bimatoprost and latanoprost for efficacy and safety in patients with glaucoma or ocular hypertension. Patients received bimatoprost 0.03% (n = 119) or latanoprost 0.005% (n = 113) once daily in the evening for 3 months. Visits were at prestudy, baseline (day 0), week 1, and months 1, 2, and 3. Primary outcome measures were mean IOP and the percentage of patients achieving IOP of 17 mm Hg or lower at 8:00 AM. Secondary outcome measures were diurnal IOP measurements (8:00 AM, 12 noon, 4:00 PM, 8:00 PM) at month 3 and safety measures including adverse events. Mean IOP was lower with bimatoprost than with latanoprost at all time points during the 3-month follow-up, although the between-group difference was not always statistically significant. At month 3 at 12 noon, mean IOP was as much as 1.0 mm Hg lower with bimatoprost (P = .021). Target pressures of < or = 17 mm Hg were reached more often with bimatoprost than with latanoprost at 8:00 AM (53% vs 43%; P = .029). Over all diurnal measurements at month 3, low target pressures of < or = 13, < or = 14, and < or = 15 mm Hg were achieved significantly more often with bimatoprost (P < or = .006). Both drugs were safe and well tolerated. Conjunctival hyperemia was more common with bimatoprost, while headache was more frequent with latanoprost. Bimatoprost provided lower mean pressures than latanoprost at every time point throughout the study and was statistically superior in achieving low target pressures. More patients reached low target pressures with bimatoprost.

Adverse periocular reactions to five types of prostaglandin analogs

“…The appearance frequencies of eyelid pigmentation with the use of PG analogs are reported to be 0, 2 0.8, 3 In these previous studies, [2][3][4][5][6][7][8][9][10][11][12][13][14][15] there were variations in the frequency of the administration period, method used for judging adverse reactions (by slit lamp or images), and race. Owing to differences in the administration period, the appearance frequency of eyelid pigmentation was 1.5-2.9% 4 in patients with o3 months of medication use and 0-25.9% 2,3,[5][6][7][8]15 in patients with 43 months of medication use.…”

“…Owing to differences in the administration period, the appearance frequency of eyelid pigmentation was 1.5-2.9% 4 in patients with o3 months of medication use and 0-25.9% 2,3,[5][6][7][8]15 in patients with 43 months of medication use. The appearance frequency of changes in eyelashes was 0-33.8% 4,10,12,15 in patients with o3 months of use and 0.7-77% [5][6][7][8][9][10][11]13,14 in patients with 43 months of use. In this study, the administration period was 43 months for all five types of PG analogs, and the appearance frequency ranged from 0 to 6.0% for eyelid pigmentation and 8.0 to 54.0% for eyelash changes.…”

“…The appearance of adverse reactions can be judged more accurately by comparing pictures of the eyes obtained before and after treatment, as noted in previous studies. [6][7][8][9][10]12,13 In this study, we did not photograph the pictures of eyes before administration. Therefore, we were not able to compare pictures of before and after administration.…”

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Of these, changes in eyelashes, eyelid pigmentation, iris pigmentation, hypertrichosis around the eye, appearance of iritis, and deepening of the upper eyelid sulcus are thought to be characteristic adverse reactions to PG analogs. The frequency of eyelid pigmentation was reported to be between 0 and 25.9%, [2][3][4][5][6][7][8][9] and eyelash bristles are reported to occur in 0-77.0% of patients [4][5][6][7][8][9][10][11][12][13][14][15] with PG analog use. However, no study has compared the frequency of occurrence of eyelid pigmentation and eyelash bristles with the use of five types of PG analogs.…”

Primer Açık Açılı Glokomlu ve Oküler Hipertansiyonlu Hastalarda Latanoprost, Bimatoprost ve Travoprostun Etkinliğinin Karşılaştırılması

“…19 Bimatoprost ile latanoprostun karşılaştırıldığı bir çalışmada, tedaviye başladıktan üç ay sonra saat 12.00 ve 16.00'da hastaların GİB değerleri ölçülmüş ve bimatoprost'un latanoprost'a göre GİB'yi daha çok düşürdüğü, ancak istatistiksel olarak aralarında fark olmadığı saptanmıştır. 20 Ülkemizde yapılan prostaglandin analoglarının karşılaştırıldığı çalışmalarda da travoprost, latanoprost ve bimatoprostun GİB'yi düşürücü etkileri eşit bulunmuştur. 21,22 Pek çok randomize klinik çalışmada glokomatöz görme alanı kayıplarındaki ilerlemenin GİB düşürülmesi ile azaldığı gösterilmiştir.…”